Har­mo­ny Bio­sciences buys small epilep­sy biotech for $35M, plus mile­stones

Rare neu­ro­log­i­cal dis­ease drug de­vel­op­er Har­mo­ny Bio­sciences ac­quired Epy­genix Ther­a­peu­tics and its pipeline of treat­ments for rare epilep­sy con­di­tions.

Har­mo­ny paid $35 mil­lion up­front, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER